Skip to main content

Erythromycin Base

FDA recalls

1 row

DateCompany and reasonClass
Apr 28, 2026Zydus Pharmaceuticals (USA) Inc
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Class II · Ongoing

← Back to Erythromycin Base

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).